Please login to the form below

Not currently logged in
Email:
Password:

J&J names McNeil Consumer leader

Johnson & Johnson has named Denice Torres, a former Lilly executive, to lead its McNeil Consumer Healthcare division, which recently has faced dozens of high-profile product recalls

Johnson & Johnson (J&J) has named Denice Torres, a former Lilly executive who has spent the past six years working at J&J, to lead its troubled McNeil Consumer Healthcare division, which recently has faced dozens of high-profile product recalls.

Torres, who will serve as president of the J&J unit, has been with the company since 2005, when she was hired to serve as VP, marketing, Ortho McNeil Neurologics.

In 2007, she became VP, sales & marketing, biosurgery and biopatch at J&J's medical devices company Ethicon, and in August 2009, she was named president, CNS, North America Pharmaceuticals.

Earlier in her career, Torres was with Eli Lilly for 14 years, becoming executive director by the time she left the company.

In her new position at J&J, Torres will report to Pat Mutchler, who was recently named chairman of a newly created McNeil group that is responsible for Tylenol, Motrin and other nonprescription J&J drugs.

Timeline of the McNeil Consumer Healthcare division events:
Tylenol recall prompts investigation    May 10, 2010
US recall of four children's products    June 1, 2010
Congress expands J&J probe    June 11, 2010
Johnson & Johnson cuts profit forecast    July 21, 2010
J&J consumer head retires amid probe    September 17, 2010
J&J recalls cold medications    November 26, 2010
FDA finds more problems at J&J plant    December 16, 2010
Oregon sues J&J over Motrin recall    January 13, 2011
More recalls by J&J's McNeil    January 17, 2011
J&J sales fall 0.5 per cent for 2010    January 26, 2011
FDA issues consent decree for J&J's McNeil    March 11, 2011

11th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Communication

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics